🇺🇸 FDA
Patent

US 8507195

MiRNAs dysregulated in triple-negative breast cancer

granted A61PA61P35/00

Quick answer

US patent 8507195 (MiRNAs dysregulated in triple-negative breast cancer) held by The Regents of the University of Colorado expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P35/00